» Articles » PMID: 26412300

Epidemiology of Onychomycosis in Italy: Prevalence Data and Risk Factor Identification

Overview
Journal Mycoses
Specialty Microbiology
Date 2015 Sep 29
PMID 26412300
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

The prevalence of onychomycosis differs according to geographic area and over time and is influenced by several factors. The epidemiology of onychomycosis in Italy is still unclear. To evaluate the prevalence of onychomycosis in a representative sample of the Italian population a group of Dermatologists and General Practitioners carried out an observational survey on the patients coming to their office during a 1-month period. Any patient with skin or systemic disease giving their consent was enrolled. Demographic characteristics, comorbidities, lifestyles, history of previous mycosis, clinical aspects of onychomycosis and mycological evaluation were studied. A total of 8331 patients (56.7% female and 43.3% male) were evaluated. More than half of them were aged ≥46 years. Onychomycosis was diagnosed in 14.2% of patients. Big toe and thumb were the most frequently affected nails. Onychomycosis was moderate-severe in 74.1% of the cases. Mycological tests were positive in 81.3% of the cases. Dermatophytes were found in 76.6% of the cases, yeasts in 17.2% and moulds in 6.3%. Risk factors and/or comorbidities were present in 68.2% of the cases. This survey showed a 14% prevalence of onychomycosis in the evaluated population. The main risk factors were previous onychomycosis, diabetes, hallux valgus and use of occlusive footwear.

Citing Articles

Epidemiologic, Clinical and Mycological Profile of Onychomycosis in the Hospital Setting in Benin.

Akpadjan F, Sissinto Savi De Tove Y, Tidjani A, Balola C, Dotsop L, Degboe B Dermatol Res Pract. 2024; 2024:1056753.

PMID: 39431060 PMC: 11490344. DOI: 10.1155/2024/1056753.


How effective is topical miconazole or amorolfine for mild to moderately severe onychomycosis in primary care: the Onycho Trial - a randomised double-blind placebo-controlled trial.

Watjer R, Bonten T, Sayed K, Quint K, van der Beek M, Mertens B BMJ Open. 2024; 14(5):e081914.

PMID: 38702077 PMC: 11086198. DOI: 10.1136/bmjopen-2023-081914.


Severe drug eruption from oral terbinafine for mild onychomycosis-A case report from family practice and literature review: "Just an innocent little pill?".

Watjer R, Eekhof J, Quint K, Numans M, Bonten T SAGE Open Med Case Rep. 2024; 12:2050313X241235823.

PMID: 38444697 PMC: 10913523. DOI: 10.1177/2050313X241235823.


Prevalence and risk predictors of onychomycosis in patients on hemodialysis: an observation, prospective, and unicenter study in Brazil.

Bersano J, Cordeiro M, Marson F Front Med (Lausanne). 2023; 10:1268324.

PMID: 38076229 PMC: 10701520. DOI: 10.3389/fmed.2023.1268324.


Effect of the 1064 nm Nd: YAG Laser on the MICs of Antifungals Used in Clinical Practice for the Treatment of Fungal Nail Infections.

Razavyoon T, Jamal Hashemi S, Mansouri P, Daie Ghazvini R, Khodavaisy S, Bakhshi H J Lasers Med Sci. 2023; 14:e35.

PMID: 38028881 PMC: 10658113. DOI: 10.34172/jlms.2023.35.